Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider Buys in This Fast Growing but Loss Generating Company – DexCom, Inc. (DXCM): Medtronic, Inc. (MDT), Boston Scientific Corporation (BSX)

Page 1 of 2

Recently, Dr. Jay Skyler, a director of DexCom, Inc. (NASDAQ:DXCM), spent nearly $1.1 million to buy 70,000 shares of the company at around $15.50 per share. Since Nov. 2011, DexCom’s share price has experienced a significant rise, from around $7 per share to $17 per share. Should investors be bullish about DexCom following its huge insider buy? Let’s find out.

A glucose monitoring business

DexCom, Inc. (DXCM)

DexCom is a medical device company focusing on glucose monitoring systems mainly for diabetes patient with two main product lines: Ambulatory product line including SEVEN PLUS and G4 PLANTINUM and In-Hospital product line including GlucoClear. DexCom, Inc. (NASDAQ:DXCM) has around 71 direct sales personnel to call on physicians and diabetes educators who could influence patient adoption of continuous glucose monitoring. The majority of its sales, $93 million, or nearly 93% of the total 2012 revenue, was generated from the product revenue while the development grant and other revenue contributed only $6.9 million in 2012 sales.

A fast growing top line and consistent operating losses

Since 2006, DexCom, Inc. (NASDAQ:DXCM) has experienced a huge growth in its revenue, increasing from $2 million in 2006 to $100 million in 2012. However, it consistently generated losses in the past seven years, varying in the range of -$45 million to -$56 million. The losses were due to the huge R&D costs and huge SG&A expenses. However, with the increasing revenue over time, DexCom has gradually reduced the percentage of R&D and SG&A expenses over revenue. In 2012, while the R&D expenses accounted for 39.54% of the total revenue, SG&A costs represented nearly 63% of the total sales. DexCom is quite conservatively capitalized. As of December 2012, it had $77 million in total stockholders’ equity, $49 million in cash and short-term investments, and only $7 million in total debt.

“Surf” the diabetes industry

In an interview with Life Sciences Report, William Plovanic, an analyst and managing director of Canaccord Genuity said that the key driver medical device companies on the stock market is their new product. Diabetes patients should get their blood glucose measured frequently to maintain their blood glucose levels within the normal range. Recently, DexCom, Inc. (NASDAQ:DXCM) has got PMA clearance of its G4 Platinum Continuous Glucose Monitor, with improved accuracy in the hypoglycemic range. He also had a $19 target price for DexCom. Indeed, DexCom seems to be a good business to “surf” on an increasing number of diabetes patients.

Page 1 of 2
Loading Comments...